<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02227264</url>
  </required_header>
  <id_info>
    <org_study_id>2012-005374-57</org_study_id>
    <nct_id>NCT02227264</nct_id>
  </id_info>
  <brief_title>Primary Hyperparathyroidism: Short-term Calcimimetics Treatment - Relevance for Parathyroid Surgery Decisions?</brief_title>
  <official_title>Primary Hyperparathyroidism: Short-term Calcimimetics Treatment - Relevance for Parathyroid Surgery Decisions?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Karolinska University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Karolinska Institutet</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Karolinska University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with primary hyperparathyroidism (pHPT) often present with fatigue, psychological&#xD;
      and cognitive symptoms. Improvement in these symptoms after parathyroid adenomectomy (PTX)&#xD;
      has been reported. But physicians lack a method to attribute the symptoms to pHPT and to&#xD;
      predict the reversibility after PTX.&#xD;
&#xD;
      This study aims to evaluate short-term calcimimetic treatment as a tool for predicting the&#xD;
      outcome of PTX on muscle strength, quality of life, psychological symptoms, and cognitive&#xD;
      function in patients with pHPT.&#xD;
&#xD;
      Material and Methods: 118 patients scheduled for PTX at Karolinska University Hospital,&#xD;
      Sweden, will have a four week treatment with calcimimetics (Mimpara®) before undergoing&#xD;
      surgery. Biochemicals, muscle strength, quality of life, psychological symptoms and cognitive&#xD;
      function will be analysed at baseline, after four week follow-up and postoperatively.&#xD;
&#xD;
      Hypothesis: The outcome of short-term calcimimetic treatment can predict the outcome of PTX&#xD;
      on muscle strength, quality of life, psychological symptoms, and cognitive function in&#xD;
      patients with pHPT&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study evaluates if short-term treatment with calcimimetics may be used for patients with&#xD;
      PHPT as a relevant guide in the decision of when to choose parathyroid surgery, by predicting&#xD;
      the outcome of surgical treatment.&#xD;
&#xD;
      120 ± 2 patients with primary hyperparathyroidism scheduled for parathyroid surgery will be&#xD;
      included in the study after informed consent and will receive study medication with&#xD;
      cinacalcet, Mimpara® 30 mgx1 for four weeks. In case of persistent hypercalcemia after two&#xD;
      weeks of treatment with Mimpara® 30 mgx1, the dosage of Mimpara® will be increased to 60 mg&#xD;
      daily. During the study drug treatment period, the patients will be followed closely at least&#xD;
      once a week with clinical monitoring and control of serum ionized calcium, given the risk of&#xD;
      side effects and hypocalcemia. If the concentration of ionized calcium in serum will decrease&#xD;
      to a subnormal level (&lt;1.15 mmol/l), the Mimpara® treatment will be discontinued temporarily&#xD;
      and only reinserted in a lower dose (30 mg x 1) if the concentration of ionized calcium&#xD;
      raises over 1.33 mmol/l. The size of the cohort has been decided after power estimations&#xD;
      based on the results in study part A. Both groups will go through the test panel of&#xD;
      self-rating scales described above at four occasions (Figure).&#xD;
&#xD;
      The Outcome to be registered are the changes from baseline to the end of the study medication&#xD;
      period compared to the changes postoperatively, thus the changes between the Visit 2 to Visit&#xD;
      6 and the changes between Visit 2 and Visit 7 and Visit 8 respektively.&#xD;
&#xD;
      Assessments and Procedures Visit 1: Clinical examination (general condition, neck, blood&#xD;
      pressure, cor et pulm). Screening of patients with primary hyperparathyroidism scheduled for&#xD;
      parathyroid surgery. Patient that fulfills inclusion and exclusion criteria will be asked to&#xD;
      participate in the study.&#xD;
&#xD;
      Visit 2: Informed consent is signed. Test panel of self rating scales (Quality of Life&#xD;
      Questionnaire-Core 30 (QLQ-C30), Positive States of Mind (PSOM )and Hospital Anxiety and&#xD;
      Depression scale (HAD), cognitive test (Montreal cognitive assessment (MoCA-Test)) and muscle&#xD;
      strength (Timed stand test). Blood samples are drawn within 2 weeks before and analyzed for:&#xD;
      parathyroid hormone (p-PTH), s-ionized calcium, p-total calcium, p-albumin, p-creatinine,&#xD;
      p-phosphate, s-25-OH-D-vitamin and p-TSH. Initiation of treatment with Mimpara® 30 mg x 1.&#xD;
      Clinical examination (general condition, blood pressure). For fertile women, a pregnancy test&#xD;
      is demanded before enrollment.&#xD;
&#xD;
      Visit 3: Week 1 (± 2 days); blood samples for analysis of ionized calcium. History of&#xD;
      symptoms related to hypocalcemia (paresthesias, cramps, muscle fatigue). Clinical examination&#xD;
      when indicated (general condition, blood pressure).&#xD;
&#xD;
      Visit 4: Week 2 (± 2 days); blood samples for analysis of ionized calcium. History as above.&#xD;
      Mimpara® continued, If the ionized calcium level is &gt;1.33 mmol/l: increase of dosage of&#xD;
      Mimpara® to 30 mg x 2.&#xD;
&#xD;
      Visit 5: Week 3 (± 2 days); blood samples for analysis of ionized calcium. History as above.&#xD;
      Mimpara® treatment completed.&#xD;
&#xD;
      Visit 6 (3): Week 4 (± 2 weeks in study B); Test panel of self rating scales (QLQ-C30, PSOM&#xD;
      and HAD), cognitive test (MoCA-Test) and muscle strength (Timed stand test). Blood samples&#xD;
      are drawn and analyzed for: plasma (p)-PTH, serum(s)-ionized serum calcium, p-total calcium,&#xD;
      p-albumin, p-creatinine, p-phosphate.&#xD;
&#xD;
      Visit 7 (4): Postoperative follow up, 6 (± 1 week) post surgery; Test panel of self rating&#xD;
      scales (QLQ-C30, PSOM and HAD), cognitive test (MoCA-Test) and muscle strength (Timed stand&#xD;
      test). Blood samples are drawn and analyzed for plasma p-PTH, s-ionized calcium, p-total&#xD;
      calcium, p-albumin, p-creatinine, p-phosphate, s-25-OH-D-vitamin and p-TSH.&#xD;
&#xD;
      Visit 8 (5): Postoperatively, 6 months post surgery (± 3 weeks); Test panel of self rating&#xD;
      scales (QLQ-C30, PSOM and HAD), cognitive test (MoCA-Test) and muscle strength (Timed stand&#xD;
      test). Blood samples are drawn and analyzed for plasma (p)-PTH, s-ionized calcium, p-total&#xD;
      calcium, p-albumin, p-creatinine, p-phosphate, s-25-OH-D-vitamin and p-TSH.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Predictive outcome in Quality of Life after parathyroidectomy</measure>
    <time_frame>after four weeks of calcimimetic treatment and postoperatively</time_frame>
    <description>Health related quality of life measured by EORTC QLQ-C30 (total score)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Psychological well-being</measure>
    <time_frame>After four weeks of calcimimetic treatment and postoperatively</time_frame>
    <description>Psychological well-being, evaluated with the validated form Positive States of Mind, PSOM</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anxiety and depression</measure>
    <time_frame>After four weeks of calcimimetic treatment and postoperatively</time_frame>
    <description>Depression and anxiety; evaluated with the Hospital Anxiety and Depression (HAD) scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Muscle strength</measure>
    <time_frame>After four weeks of calcimimetic treatment and postoperatively</time_frame>
    <description>Leg muscle strength measured by Timed stand-test (repeated uprise from chair)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biochemical data</measure>
    <time_frame>After four weeks of calcimimetic treatment and postoperatively</time_frame>
    <description>AE/SAE recording and safety blood samples; serum levels of p-PTH, s-ionized calcium, p-total calcium, p-albumin, p-creatinine, p-phosphate, s-25-OH-D and thyroid-stimulating hormone (TSH)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cognitive function</measure>
    <time_frame>after four weeks of calcimimetic treatment and postoperatively</time_frame>
    <description>Cognitive function evaluated with Montreal cognitive assessment (MoCA-test)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">123</enrollment>
  <condition>Primary Hyperparathyroidism</condition>
  <arm_group>
    <arm_group_label>Cinacalcet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cinacalcet, Mimpara®: 30 mgx1 for four weeks. In case of persistent hypercalcemia after two weeks of treatment with Mimpara® 30 mgx1, the dosage of Mimpara® will be increased to 60 mg daily.&#xD;
Second intervention: Parathyroid adenomectomy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cinacalcet</intervention_name>
    <description>Cinacalcet, Mimpara® 30mgx1-2 for 4 weeks</description>
    <arm_group_label>Cinacalcet</arm_group_label>
    <other_name>H05BX01</other_name>
    <other_name>Mimpara®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>parathyroid adenomectomy</intervention_name>
    <description>surgical removal of pathologic parathyroid tissue</description>
    <arm_group_label>Cinacalcet</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Primary hyperparathyroidism&#xD;
&#xD;
          -  Scheduled for parathyroid surgery&#xD;
&#xD;
          -  Age &gt;40&#xD;
&#xD;
          -  Ability to participate in all tests included in the study model&#xD;
&#xD;
          -  Signed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Breast feeding&#xD;
&#xD;
          -  Fertile woman not using contraceptives (IUD or pills)&#xD;
&#xD;
          -  Impaired kidney function, GFR &lt; 40 ml/min&#xD;
&#xD;
          -  Intolerance to Mimpara®&#xD;
&#xD;
          -  Previously treated with Mimpara®&#xD;
&#xD;
          -  Participating in other ongoing clinical study&#xD;
&#xD;
          -  Epilepsy&#xD;
&#xD;
          -  Severe hepatic impairment&#xD;
&#xD;
          -  Hypotension&#xD;
&#xD;
          -  Heart failure (NYHA class 3-4, symptoms with minimal exertion)&#xD;
&#xD;
          -  Medication with ketoconazole (oral) or tricyclic antidepressants&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Inga-Lena Nilsson, M.D., Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Karolinska UH</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Inga-Lena Y Nilsson, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Karolinska UH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Karolinska University Hospital</name>
      <address>
        <city>Stockholm</city>
        <zip>171 76</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <link>
    <url>http://www.karolinska.se/</url>
    <description>Karolinska University Hospital</description>
  </link>
  <link>
    <url>http://ki.se/</url>
    <description>Karolinska Institute</description>
  </link>
  <link>
    <url>http://www.epn.se</url>
    <description>Ethical Review Board</description>
  </link>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>August 17, 2014</study_first_submitted>
  <study_first_submitted_qc>August 27, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 28, 2014</study_first_posted>
  <last_update_submitted>January 6, 2020</last_update_submitted>
  <last_update_submitted_qc>January 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Karolinska University Hospital</investigator_affiliation>
    <investigator_full_name>Inga-Lena Nilsson</investigator_full_name>
    <investigator_title>M.D., Ph.D; Assoc.prof.</investigator_title>
  </responsible_party>
  <keyword>Primary hyperparathyroidism</keyword>
  <keyword>Calcimimetic Agents</keyword>
  <keyword>Parathyroid adenomectomy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperparathyroidism</mesh_term>
    <mesh_term>Hyperparathyroidism, Primary</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parathyroid Hormone</mesh_term>
    <mesh_term>Cinacalcet</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

